 |
test site |
|
|||||
| Executive Editor.....Anne-Merete Robbs CEO..............Stan Swartz | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| "Dr. Vollmer is close to a MS cure..but..he needs you to help by joining a trial!" | ||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "Plus...You'll receive all medication and study based procedures at NO CHARGE" . |
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
| "MY EDUCATIONAL VIDEO ON MS" | ||||||||||||||||||||||
 For Broadband Users Runtime: 4:17 WMV |
||||||||||||||||||||||
| "THE VOLUNTARY SUSPENSION OF TYSABRI BY BIOGEN IDEC AND ELAN" | ||||||||||||||||||||||
 For Broadband Users Runtime: 4:17 WMV |
||||||||||||||||||||||
 |
||||||||||||||||||||||
 |
||||||||||||||||||||||
| Timothy L. Vollmer M.D. Director, Barrow NeuroImmunology Program Barrow Neurological Institute St. Joseph's Hospital and Medical Center |
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||
|
||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||
| December 2005 | ||||||||||||||||||||||
| January 2006 | ||||||||||||||||||||||
| May 2006 | ||||||||||||||||||||||
| June 2006 | ||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||
| October 2013 | ||||||||||||||||||||||
| November 2013 | ||||||||||||||||||||||
| December 2013 | ||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||
Wednesday
Advancement in stem cell therapies show potential for multiple sclerosis care
A report outlining the progress of stem cell therapy - and new methods which could lead to an eventual cure for multiple sclerosis and other degenerative diseases - has been published today.
More than 100,000 people in the UK are affected by multiple sclerosis (MS), with 2.5 million people, mostly young adults, affected worldwide.The cause of multiple sclerosis is yet unknown, but is thought to occur as a result of brain cells becoming damaged, with conducting fibres in the brain being attacked by the body's immune system.
The immune system damages the protective insulating layer called a 'myelin sheath', which disrupts the signals travelling along nerve fibres and can partially or completely disrupt transmission.
Due to the nature of our central nervous system, the symptoms of MS in each instance can vary according to which nerves are damaged.
MS costs the EU economy €9 billion each year, largely due to the progressively disabling nature of the disease. Until recently, therapy has focused upon using stem cells to replace oligodendrites, cells which produce myelin. This approach, however, has had limited application in the treatment of MS.
The authors of the paper published in the Lancet, Professor Neil Scolding and a team from Frenchay Hospital in Bristol, UK, have suggested that new hope may lie in an increasingly advanced understanding of stem cells and their reparative properties.
Click here to read the full article from informationdaily.com
Saturday
GOOD STORIES: FEATURED ARTICLE
8 Ways to Live Better With MS
Managing your life with MS isn't just about dealing with the symptoms you have right now. It's about thinking through what could happen in future -- the possible effects on your job, family, and finances -- and preparing for them.
FREE.... MIGRAINES
Thursday
POSSIBLY CAN'T USE FOR TIM VOLLMER'S COLUMN*** STAN READ AND DECIDE
SEARCHING FOR NEW WAYS TO TREAT MS
Dr. Tim Vollmer, co-director of the Rocky Mountain MS Center at Anschutz Medical Campus, has recently launched an investigator-initiated study to explore the use of combination therapies for the treatment of multiple sclerosis. Combination therapy is a strategy that uses existing drugs in combination
with each other to achieve better disease management with fewer side effects. This approach has been used very successfully in other diseases, for example HIV/AIDS, to help people attain a “disease-free” state. The drug combination to be investigated in this study includes Copaxone, an injectable therapy used to treat MS and Rituxan, an intravenous therapy used to treat certain lymphomas and rheumatoid arthritis. Both drugs have been in use for a long time and have excellent safety profiles. They also have different effects on the immune system. Rituxan is an anti-B cell therapy and Copaxone encourages the development of new regulatory B cells. The theory behind using the drugs in combination is that Rituxan will deplete the destructive B cells and Copaxone will generate new B cells. Using this sort of one-two punch, we might be able to reprogram the immune system in way that is more effective than the treatments now available.
Participants in the study must be between the ages of 18 and 55 and live in Colorado or be able to visit Colorado frequently. They must be diagnosed with CIS (clinically isolated syndrome), relapsing-remitting MS, or secondary- progressive MS and have evidence of a relapse in the past twelve months.
Study participants will receive two infusions of either Rituxan or placebo
at the start of the trial and then begin daily Copaxone injections. MRIs will be done every six months. Participants will be followed with monthly phone “visits” and with office exams and lab tests every three months so their progress can be carefully monitored. If someone has a relapse or begins to experience new disease activity the study stops and a different treatment is started. In the past few years there have been several small studies that explored the use of Rituxan as a treatment for MS and the results were clearly positive. The drug is not FDA-approved for MS, however, which means that insurance companies usually won’t pay for its use. Participants in this clinical trial will receive the drug at no cost to them or their insurance company.
Dr. Tim Vollmer, co-director of the Rocky Mountain MS Center at Anschutz Medical Campus, has recently launched an investigator-initiated study to explore the use of combination therapies for the treatment of multiple sclerosis. Combination therapy is a strategy that uses existing drugs in combination
with each other to achieve better disease management with fewer side effects. This approach has been used very successfully in other diseases, for example HIV/AIDS, to help people attain a “disease-free” state. The drug combination to be investigated in this study includes Copaxone, an injectable therapy used to treat MS and Rituxan, an intravenous therapy used to treat certain lymphomas and rheumatoid arthritis. Both drugs have been in use for a long time and have excellent safety profiles. They also have different effects on the immune system. Rituxan is an anti-B cell therapy and Copaxone encourages the development of new regulatory B cells. The theory behind using the drugs in combination is that Rituxan will deplete the destructive B cells and Copaxone will generate new B cells. Using this sort of one-two punch, we might be able to reprogram the immune system in way that is more effective than the treatments now available.
Participants in the study must be between the ages of 18 and 55 and live in Colorado or be able to visit Colorado frequently. They must be diagnosed with CIS (clinically isolated syndrome), relapsing-remitting MS, or secondary- progressive MS and have evidence of a relapse in the past twelve months.
Study participants will receive two infusions of either Rituxan or placebo
at the start of the trial and then begin daily Copaxone injections. MRIs will be done every six months. Participants will be followed with monthly phone “visits” and with office exams and lab tests every three months so their progress can be carefully monitored. If someone has a relapse or begins to experience new disease activity the study stops and a different treatment is started. In the past few years there have been several small studies that explored the use of Rituxan as a treatment for MS and the results were clearly positive. The drug is not FDA-approved for MS, however, which means that insurance companies usually won’t pay for its use. Participants in this clinical trial will receive the drug at no cost to them or their insurance company.
FORMER BRISTOL-MYERS SQUIBB EXECUTIVE SENT TO PRISON FOR INSIDER TRADING
When Bristol-Myers Squibb ($BMY) wanted to take over a company, execs turns to Robert Ramnarine in their Princeton, NJ, office to do the confidential due diligence work on the target company's pension plan. But his plan for feathering his own nest with the insider information he picked up is leading to early retirement--in prison. Ramnarine was sentenced to one year and one day of jail time after pleading guilty to one count of securities fraud related to the ex-exec's purchase of options on Amylin stock as Bristol-Myers readied its $5.3 billion buyout last year. As Reuters reported, Ramnarine did a little online sleuthing on how insider trading is detected--evidently without realizing the Internet searches on insider trading can help make a case against you.
READ MORE
When Bristol-Myers Squibb ($BMY) wanted to take over a company, execs turns to Robert Ramnarine in their Princeton, NJ, office to do the confidential due diligence work on the target company's pension plan. But his plan for feathering his own nest with the insider information he picked up is leading to early retirement--in prison. Ramnarine was sentenced to one year and one day of jail time after pleading guilty to one count of securities fraud related to the ex-exec's purchase of options on Amylin stock as Bristol-Myers readied its $5.3 billion buyout last year. As Reuters reported, Ramnarine did a little online sleuthing on how insider trading is detected--evidently without realizing the Internet searches on insider trading can help make a case against you.
READ MORE
Wednesday
coming tomorrow style
"WE'RE PUTTING TOGETHER A STORY FOR YOU TO READ TOMORROW ABOUT A HUGE COMMERCIAL MEDICAL MARIJUANA GROWING FIELD ALONG WITH INFO FROM A NEUROLOGIST THAT'S VISITED IT! IT WILL ALL BE IN TOMORROW'S NEWS!"
LOOK AT THE PHOTO BELOW!
I'ts the growing field that the Neurologist is going to be telling you about tomorrow on MSnewsChannel.com
THIS IS THE MEDICAL MARIJUANA GROWING FIELD WE'RE WRITING ABOUT FOR OUR STORY IN TOMORROW'S NEWS ON MSNC (MSnewsChannel.com)
PS....PLEASE SHARE THIS STORY WITH ALL OF YOUR FRIENDS! PART OF MY JOB IS TO HELP GET MORE MSers LIKE MYSELF TO VISIT OUR www.MSnewsChannel.com every day!